Prospective Observational Study of Bisphosphonate-Related Osteonecrosis of the Jaw in Multiple Myeloma: Microbiota Profiling and Cytokine Expression
Author
Badros, Ashraf ZMeddeb, Mariam
Weikel, Dianna
Philip, Sunita
Milliron, Todd
Lapidus, Rena
Hester, Lisa
Goloubeva, Olga
Meiller, Timothy F
Mongodin, Emmanuel F
Date
2021-06-24Journal
Frontiers in OncologyPublisher
Frontiers Media S.A.Type
Article
Metadata
Show full item recordAbstract
Purpose: Define incidence and risk factors of osteonecrosis of the jaw (ONJ) and explore oral microbial signatures and host immune response as reflected by cytokine changes in saliva and serum in multiple myeloma (MM) patients on bisphosphate (BP) therapy. Patients and Methods: A single center observational prospective study of MM patients (n = 110) on >2 years of BP, none had ONJ at enrollment. Patients were followed every 3 months for 18 months with clinical/dental examination and serial measurements of inflammatory cytokines, bone turnover markers, and angiogenic growth factors. Oral microbiota was characterized by sequencing of 16S rRNA gene from saliva. Results: Over the study period 14 patients (13%) developed BRONJ, at a median of 5.7 years (95% CI: 1.9–12.0) from MM diagnosis. Chronic periodontal disease was the main clinically observed risk factor. Oral microbial profiling revealed lower bacterial richness/diversity in BRONJ. Streptococcus intermedius, S. mutans, and S. perioris were abundant in controls; S. sonstellatus and S anginosus were prevalent in BRONJ. In the saliva, at baseline patients who developed BRONJ had higher levels of MIP-1β; TNF-α and IL-6 compared to those without BRONJ, cytokine profile consistent with M-1 macrophage activation. In the serum, patients with BRONJ have significantly lower levels of TGF beta and VEGF over the study period. Conclusion: Periodontal disease associated with low microbial diversity and predominance of invasive species with a proinflammatory cytokine profile leading to tissue damage and alteration of immunity seems to be the main culprit in pathogenesis of BRONJ.Rights/Terms
Copyright © 2021 Badros, Meddeb, Weikel, Philip, Milliron, Lapidus, Hester, Goloubeva, Meiller and Mongodin.Identifier to cite or link to this item
http://hdl.handle.net/10713/16184ae974a485f413a2113503eed53cd6c53
10.3389/fonc.2021.704722
Scopus Count
Collections
Related articles
- Oral microbiota and host innate immune response in bisphosphonate-related osteonecrosis of the jaw.
- Authors: Pushalkar S, Li X, Kurago Z, Ramanathapuram LV, Matsumura S, Fleisher KE, Glickman R, Yan W, Li Y, Saxena D
- Issue date: 2014 Dec
- Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator.
- Authors: O'Ryan FS, Khoury S, Liao W, Han MM, Hui RL, Baer D, Martin D, Liberty D, Lo JC
- Issue date: 2009 Jul
- Serum Markers of Bone Turnover and Angiogenesis in Patients With Bisphosphonate-Related Osteonecrosis of the Jaw After Discontinuation of Long-Term Intravenous Bisphosphonate Therapy.
- Authors: Thumbigere-Math V, Michalowicz BS, Hughes PJ, Basi DL, Tsai ML, Swenson KK, Rockwell L, Gopalakrishnan R
- Issue date: 2016 Apr
- Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) therapy. A critical review.
- Authors: Vescovi P, Nammour S
- Issue date: 2010 Apr
- IL-17-mediated M1/M2 macrophage alteration contributes to pathogenesis of bisphosphonate-related osteonecrosis of the jaws.
- Authors: Zhang Q, Atsuta I, Liu S, Chen C, Shi S, Shi S, Le AD
- Issue date: 2013 Jun 15